Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
Moiez Ali(Emory University), Kris C. Wood(Duke University), Alberto Bardelli(IFOM), Erin Kaltenbrun(Duke University), Grace R. Anderson(Duke University), Sarah Jo Stephens(Duke University), Christopher M. Counter(Duke University), Sabrina Arena(Candiolo Cancer Institute)
Cited by 46
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Toward understanding and exploiting tumor heterogeneity
|Nature Medicine|2015|770
Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation
|Journal of Clinical Investigation|2014|717